Crucially, it is now established that both gain‐of‐function mutations and non‐activating mutations induce macrothrombocytopenia through suppression of the αIIbβ3/RhoA/cytoskeletal signalling axis [41]. The gene discussed is RHOA; the disease is Macrothrombocytopenia.